• Comparison of QTc Data Analysis Methods Recommended by the ICH E14 Guidance and Exposure-Response Analysis: Case Study of a Thorough QT Study of Asenapine.. S. Chapel, M. Hutmacher, H. Bockbrader, R de Greef, R. Lalonde, Clinical Pharmacology & Therapeutics 2010:89:75-80.
  • Exposure-Response Analysis in Patients with Schizophrenia to Assess the Effecct of Asenapine on QTc Prolongation.. S. Chapel, M. Hutmacher, G. Haig, H. Bockbrader, R. de Greef, S.. Preskorn, and R. Lalonde. J. Clin. Pharmacol. 2009;49:1297-1308.
  • Joint Modeling of Dizziness, Drowsiness, and Dropout Associated with Pregabalin and Placebo Treatment of Generalized Anxiety Disorder.. B. Frame, R. Miller, and M. Hutmacher. J. PK & PD 2009;36:565-584.
  • Modeling and Simulation to a Support Dose Selection and Clinical Development of SC-75416, a Selective COX-2 inhibitor for the Treatment of Acute and Chronic Pain.. K. Kowalski, S. Olson, A. Remmers, and M. Hutmacher, Clinical Pharmacology & Therapeutics 2008;83:857-866.
  • Exposure-Response Modeling Using Latent Variables for the Efficacy of a JAK3 Inhibitor Administered to Rheumatoid Arthritis Patients.. M. Hutmacher, Sl. Krishnaswami, and K. Kowalski. J. PK & PD 2008;35:139-157.
  • An Alternative Method for Population Pharmacokinetic Data Analysis under Noncompliance.. P. Gupta, M. Hutmacher, B. Frame, and R. Miller J. PK & PD 2008;35:219-233.
  • Exposure-response Analysis for Spontaneously Reported Dizziness in Pregabalin-treated Patient With Generalized Anxiety Disorder.. K. Ito, M. Hutmacher, J. Liu, R. Qiu, B. Frame, and R. Miller. Clinical Pharmacology & Therapeutics 2008;84:127-135.